GlassScriptPhysician profile
Jamie Sims
NPI 1174063812
$1,474.86
in general payments reported to CMS, 2019-2025
21 companies · $60.18 in 2025
The $60.18 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $723 · 2022: $388 · 2023: $163 · 2024: $140 · 2025: $60.18.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $346 · Education: $18.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $345.63 |
| Education | $18.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astellas Pharma US INC | $321.48 | 2021-2023 | Myrbetriq |
| Pfizer INC. | $261.57 | 2021-2023 | |
| Novartis Pharmaceuticals Corporation | $147.60 | 2022-2023 | Leqvio |
| Glaxosmithkline, LLC. | $142.79 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $139.34 | 2022-2024 | |
| Janssen Pharmaceuticals, INC | $87.49 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $82.52 | 2021-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $43.59 | 2021-2022 | |
| Phathom Pharmaceuticals, INC. | $35.75 | 2025 | Voquezna |
| Abbvie INC. | $26.27 | 2021 | |
| Boston Scientific Corporation | $24.43 | 2025 | General - Pain Management |
| Amarin Pharma, INC. | $19.66 | 2022 | |
| Xeris Pharmaceuticals, INC. | $19.54 | 2022 | |
| Medtronic, INC. | $18.00 | 2024 | |
| Novo Nordisk INC | $17.36 | 2022 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $16.56 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.35 | 2021 | |
| G Medical Diagnostic Services, INC. | $15.35 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $13.77 | 2021 | |
| Astrazeneca Pharmaceuticals LP | $13.53 | 2021 | |
| Philips North America LLC | $12.91 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamie Sims listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.